What is Tribute Pharmaceuticals Canada Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Tribute Pharmaceuticals Canada Sloan Ratio % Chart
Competitive Comparison of Tribute Pharmaceuticals Canada's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tribute Pharmaceuticals Canada's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Tribute Pharmaceuticals Canada's Sloan Ratio % falls into.
Tribute Pharmaceuticals Canada Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Tribute Pharmaceuticals Canada's Net Income for the trailing twelve months (TTM) ended in Sep. 2015 was -0.832 (Dec. 2014 ) + -4.106 (Mar. 2015 ) + -7.085 (Jun. 2015 ) + 1.19 (Sep. 2015 ) = $-10.83 Mil.
Tribute Pharmaceuticals Canada's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2015 was 1.517 (Dec. 2014 ) + -2.093 (Mar. 2015 ) + -1.431 (Jun. 2015 ) + -0.243 (Sep. 2015 ) = $-2.25 Mil.
Tribute Pharmaceuticals Canada's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2015 was -28.051 (Dec. 2014 ) + -0.071 (Mar. 2015 ) + -11.945 (Jun. 2015 ) + -2.57 (Sep. 2015 ) = $-42.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tribute Pharmaceuticals Canada (OTCPK:TBUFF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2015, Tribute Pharmaceuticals Canada has a Sloan Ratio of 40.11%, indicating earnings are more likely to be made up of accruals.
Tribute Pharmaceuticals Canada Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBUFF has been successfully added to your 